Patient characteristics at TCZ start. All patients had severe JIA-associated uveitis refractory to corticosteroids and systemic immunosuppression (n = 17 patients). Values are n (%) unless otherwise specified.
| Characteristics | Values |
|---|---|
| Age, yrs, mean ± SD* | 15.3 ± 6.9 |
| Male:female, n | 3:14 |
| Age at JIA diagnosis, yrs, mean ± SD | 3.1 ± 2.1 |
| Age at uveitis diagnosis, yrs, mean ± SD | 4.3 ± 2.6 |
| ILAR classification | |
| Persistent oligoarthritis | 5 (29.4) |
| Extended oligoarthritis | 4 (23.5) |
| Polyarthritis | 7 (41.2) |
| Undifferentiated | 1 (5.9) |
| ANA+ | 16 (94.1) |
| HLA-B27+ | 2 (11.8) |
| RF+ | 0 (0) |
| Uveitis type: anterior, no. patients (%) | 17 (100) |
| Secondary ocular complications | |
| Patients with complications, no. patients (%) | 13 (76.5) |
| Cataract | 10 (58.8) |
| Band keratopathy | 9 (52.9) |
| Synechia | 7 (41.2) |
| Ocular hypertension | 4 (23.5) |
| Glaucoma | 4 (23.5) |
| Macular edema | 5 (29.4) |
| Epiretinal membrane | 3 (17.6) |
| Optic disc edema | 4 (23.5) |
| Ocular hypotony or phthisis | 2 (11.8) |
| Retinal detachment | 1 (5.9) |
| Amblyopia | 1 (5.9) |
| Active arthritis | 11 (64.7) |
| Treatment history before baseline, patients | |
| Methotrexate | 16 (94.1) |
| Cyclosporine | 5 (29.4) |
| Mycophenolate mofetil | 5 (29.4) |
| Leflunomide | 1 (5.9) |
| Azathioprine | 7 (41.2) |
| Infliximab | 13 (76.5) |
| Adalimumab | 7 (41.2) |
| Etanercept | 2 (11.8) |
| Rituximab | 1 (5.9) |
| Golimumab | 7 (41.2) |
| Treatment at baseline, patients | |
| Topical corticosteroids | 14 (82.4) |
| Systemic corticosteroids | 7 (41.2) |
| Methotrexate | 10 (58.8) |
| Cyclosporine | 2 (11.8) |
| Leflunomide | 4 (23.5) |
| Infliximab | 2 (11.8) |
| Adalimumab | 4 (23.5) |
| Abatacept | 3 (17.6) |
↵* Age at the time of starting TCZ therapy. TCZ: tocilizumab; JIA: juvenile idiopathic arthritis; ILAR: International League of Associations for Rheumatology; ANA: antinuclear antibodies; RF: rheumatoid factor.